Dimethylformamide → HCID 59592950, compound
Reaction equation
[O:1]1[CH2:5][CH2:4][NH:3][C:2]1=[O:6].[H-].[Na+].Br[CH2:10][C:11]1[S:19][C:18]2[C:17]([N:20]3[CH2:25][CH2:24][O:23][CH2:22][CH2:21]3)=[N:16][C:15](Cl)=[N:14][C:13]=2[CH:12]=1.C[N:28]([CH:30]=O)C>>[NH:28]1[C:30]2[C:18](=[C:13]([C:15]3[N:16]=[C:17]([N:20]4[CH2:25][CH2:24][O:23][CH2:22][CH2:21]4)[C:18]4[S:19][C:11]([CH2:10][N:3]5[CH2:4][CH2:5][O:1][C:2]5=[O:6])=[CH:12][C:13]=4[N:14]=3)[CH:12]=[CH:11][CH:10]=2)[CH:17]=[N:16]1Participants
5
Procedure
To a solution of 2-oxazolidinone (50 mg, 0.6 mmol) in DMF (2 mL) at 0° C. NaH (60% in mineral oil; 0.7 mmol) was added. After 15 minutes, 6-(bromomethyl)-2-chloro-4-morpholinothieno[3,2-d]pyrimidine 30 from Example 9 (200 mg, 0.6 mmol) in DMF (0.5 mL) was added and the reaction stirred 15 min. The reaction was quenched by the addition of saturated aqueous ammonium chloride. The aqueous layer was extracted with EtOAc. The combined organics were dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was utilized in a Suzuki coupling using General Procedure A with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 7 to provide 311 after reverse phase HPLC purification (6 mg). MS (Q1) 437 (M)+
Workup
- customat 0° C
- customThe reaction was quenched by the addition of saturated aqueous ammonium chloride
- extractionThe aqueous layer was extracted with EtOAc
- dry with materialThe combined organics were dried over Na2SO4
- filtrationfiltered
- concentrationconcentrated in vacuo
Sources & evidence
- ORD record
- ord-9536d7e9d352434dbf5828a66c4e1e4e
- Source dataset
- uspto-grants-2013_05
- Patent number
- US08450315B2
Reaction notes
Loading…